SIGLEC-1 Expression in a Cohort of Patients With Lupus Erythematosus Treated With Anifrolumab

This cohort study evaluates the usefulness of measuring SIGLEC-1 expression for tracking response to anifrolumab therapy in patients with lupus erythematosus.

Corresponding Author: Deepak A. Rao, MD, PhD, Brigham and Women’s Hospital, Harvard Medical School, 60 Fenwood Rd, Room 6002R, Boston, MA 02115 (darao@bwh.harvard.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.